While Indian pharmaceutical industry has rightfully gained the epithet ‘pharmacy to the world.’, it has also become highly import dependant for its key starting material (KSM), intermediates and active pharmaceutical ingredients (APIs).
Over the past two decades, India’s reliance has grown for imports of low-cost intermediates and APIs. Over-dependence on imports has increased the threat to the Nation’s health security. The COVID-19 crisis has brought forth the need for India to have its own strengths and supplies of API for its robust pharma sector and the Government’s recently approved package of INR9,940 crore shall boost the domestic production of bulk drugs and exports.
This report, published jointly by CII and KPMG, is a holistic research-based analysis and comparison of policies and incentives for bulk drug industry from India and China. The report captures the current state of the Indian bulk drug industry, identifies challenges, comparison between India and China and highlights key recommendations to establish self-sufficiency in APIs.